Actovegin, 40 mg/ml 10 ml 5 pcs

Actovegin positively affects the transport and utilization of glucose, stimulates oxygen consumption (which leads to stabilization of plasma cell membranes during ischemia and reduction of lactate formation) thus having an antihypoxic effect, which begins to appear 30 min (10-30 min) later after parenteral administration and reaches a maximum average of 3 h (2-6 h).

Actovegin increases concentrations of ATP, LDL, phosphocreatine and the amino acids glutamate, aspartate and GABA.

The use of Actovegin to accelerate wound healing is also based on the data mentioned above. Not only morphological but also biochemical parameters of granulations are improved – concentration of DNA, hemoglobin and hydroxyproline increases.

Indications

Active ingredient

Composition

1 ampoule contains:

the active ingredient:

Actovegin® concentrate (in terms of dry deproteinized calf blood hemoderivate) 1) – 400.0 mg;

complementary substance:

water for injection – up to 10 ml.

1) Aktovegin® concentrate contains sodium chloride in the form of sodium and chlorine ions, which are components of calf blood. Sodium chloride is not added or removed during the production of the concentrate.

The sodium chloride content is about 53.6 mg (for 2 ml ampoules), about 134.0 mg (for 5 ml ampoules) and about 268.0 mg (for 10 ml ampoules).

How to take, the dosage

B/a, IV (including as an infusion) and IM. Due to the potential for anaphylactic reactions, it is recommended to test before starting the infusion.

Depending on the severity of the clinical picture, 10-20 ml/day w/v or w/a; then 5 ml w/v or 5 ml w/v.

When administered as infusion 10-20 ml of Actovegin® is added to 200-300 ml of basic solution (0.9% sodium chloride solution or 5% dextrose solution). Infusion rate: about 2 ml/min.

Metabolic and vascular disorders of the brain: at the beginning of treatment 10 ml by IV daily for two weeks, then 5-10 ml by IV 3-4 times a week for at least 2 weeks.

Ischemic stroke: 20-50 ml in 200-300 ml of the basic solution by IV drip daily for 1 week, then 10 – 20 ml by IV drip for 2 weeks.

Peripheral (arterial and venous) vascular disorders and their consequences: 20-30 ml of drug in 200 ml of basic solution w/a or w/v daily; duration of treatment about 4 weeks.

Wound healing: 10 ml w/o or 5 ml w/o daily or 3-4 times a week depending on the healing process (in addition to local treatment with Actovegin® in dosage forms for local use).

Prevention and treatment of radiation lesions of the skin and mucous membranes during radiotherapy: The average dose is 5 ml by IV daily at intervals of radiation exposure.

Radiation cystitis: 10 ml transurethral daily in combination with antibiotic therapy.

Interaction

It is currently unknown.

Special Instructions

Because of the possibility of an anaphylactic reaction, a test injection (2 ml intramuscularly) is recommended.

The solution for injection has a slightly yellowish tint. The color intensity may vary from batch to batch depending on the characteristics of the starting materials used, but this does not adversely affect the activity or tolerability of the drug.

In case of intramuscular administration, administer slowly not more than 5 ml.

Do not use an opaque solution or one containing particles. Once the ampoule is opened, the solution should not be stored.

Contraindications

Side effects

Allergic reactions (skin rash, skin hyperemia, hyperthermia) up to anaphylactic shock.